<DOC>
	<DOCNO>NCT00760565</DOCNO>
	<brief_summary>This single center , multiple ascend dose study assess safety , tolerability , pharmacokinetics pharmacodynamics RO4905417 different dos healthy volunteer patient peripheral arterial disease . Three group 10 healthy volunteer receive RO4905417 ( either 3mg/kg , 7mg/kg 20mg/kg ) placebo iv every 28 day total 3 infusion . In addition , two group 6 PAD patient receive RO4905417 ( either 3mg/kg , 7mg/kg ) placebo 1 group 20 PAD patient receive 20mg/kg RO4905417 placebo iv every 28 day total three infusion . The study adaptive design ongoing assessment safety tolerability prior initiation next dose . All subject receive 3 dos RO4905417 match placebo 28 day interval . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study RO4905417 Healthy Volunteers Patients With Peripheral Arterial Disease ( PAD ) .</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>healthy male female age 1865 year ( Arms 1,2,5,6,9,10 ) ; BMI 1830kg/m2 ( Arms 1,2,5,6,9,10 ) ; male female age 4575 year confirm stable PAD ( Arms 3,4,7,8,11,12 ) ; stable dose statin , aspirin clopidogrel least one month prior study ( Arms 3,4,7,8,11,12 ) ; BMI 17.535kg/m2 ( Arms 3,4,7,8,11,12 ) . patient pain rest and/or local complication ; history cardiovascular event within previous 6 month ; treatment drug potentially affect coagulation time platelet aggregation ( except aspirin clopidogrel ) ; evidence hepatic renal impairment ; history bleeding disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>